



Clinical trial results:

An Open-Label Extension Study to Allow Continued Dosing and/or Follow-up of Patients who have had Previous Exposure to Poziotinib Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2020-005213-40 |
| Trial protocol | IT |
| Global end of trial date | 03 March 2023 |

Results information

| | |
|--------------------------------|---------------|
| Result version number | v1 (current) |
| This version publication date | 19 April 2024 |
| First version publication date | 19 April 2024 |

Trial information

Trial identification

| | |
|-----------------------|-------------|
| Sponsor protocol code | SPI-POZ-501 |
|-----------------------|-------------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT03744715 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | Spectrum Pharmaceuticals, Inc. |
| Sponsor organisation address | Research and Development Office, 157 Technology Dr W, Irvine, California, United States, 92618 |
| Public contact | Howard Franklin, Assertio Holdings, 00 224 419 7106, Hfranklin@assertiotx.com |
| Scientific contact | Howard Franklin, Assertio Holdings, 00 224 419 7106, Hfranklin@assertiotx.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|---------------|
| Analysis stage | Final |
| Date of interim/final analysis | 03 March 2023 |
| Is this the analysis of the primary completion data? | No |
| Global end of trial reached? | Yes |
| Global end of trial date | 03 March 2023 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

The main objective of this extension study was to provide the clinical benefit of poziotinib to participants who were responding to treatment.

Protection of trial subjects:

This study was conducted in accordance with good clinical practice (GCP) and with the internal standard operating procedures (SOPs) of Spectrum Pharmaceuticals, Inc. A study-specific written informed consent was signed by each subject prior to any study-related assessments or procedures that were conducted.

Background therapy: -

Evidence for comparator: -

| | |
|---|-----------------|
| Actual start date of recruitment | 11 October 2018 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|------------------|
| Country: Number of subjects enrolled | United States: 7 |
| Worldwide total number of subjects | 7 |
| EEA total number of subjects | 0 |

Notes:

Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 4 |
| From 65 to 84 years | 3 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

Participants were enrolled at investigative sites across the United States from 11 October 2018 to 03 March 2023.

Pre-assignment

Screening details:

A total of 7 participants were enrolled and dosed with Pozitotinib.

Period 1

| | |
|------------------------------|---------------------------------|
| Period 1 title | Overall Period (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Not applicable |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Pozitotinib 6 mg |

Arm description:

Participants started pozitotinib 6 mg twice a day (BID) in a 21-day cycle in the current study after having received 16 mg once daily (QD) in the parent study NCT03318939.

| | |
|--|-------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Pozitotinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Modified-release tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Pozitotinib 6 mg administered orally, once daily

| | |
|------------------|------------------|
| Arm title | Pozitotinib 8 mg |
|------------------|------------------|

Arm description:

Participants started pozitotinib 8 mg QD in a 21-day cycle in the current study after having received 16 mg QD in the parent study NCT03318939.

| | |
|--|-------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Pozitotinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Modified-release tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Pozitotinib 8 mg administered orally, once daily

| | |
|------------------|-------------------|
| Arm title | Pozitotinib 12 mg |
|------------------|-------------------|

Arm description:

Participants started pozitotinib 12 mg QD in a 21-day cycle in the current study after having received same dose in the parent study NCT03318939.

| | |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

| | |
|---|-------------------------|
| Investigational medicinal product name | Poziotinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Modified-release tablet |
| Routes of administration | Oral use |
| Dosage and administration details: | |
| Poziotinib 12 mg administered orally, once daily | |
| Arm title | Poziotinib 14 mg |
| Arm description: | |
| Participants started poziotinib 14 mg QD in a 21-day cycle in the current study after having received 16 mg QD in the parent study NCT03318939. | |
| Arm type | Experimental |
| Investigational medicinal product name | Poziotinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Modified-release tablet |
| Routes of administration | Oral use |
| Dosage and administration details: | |
| Poziotinib 14 mg administered orally, once daily | |
| Arm title | Poziotinib 16 mg |
| Arm description: | |
| Participants started poziotinib at 16 mg QD in a 21-day cycle in the current study after having received 12 mg QD in the parent study NCT03804515. | |
| Arm type | Experimental |
| Investigational medicinal product name | Poziotinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Modified-release tablet |
| Routes of administration | Oral use |
| Dosage and administration details: | |
| Poziotinib 16 mg administered orally, once daily | |
| Arm title | Poziotinib 24 mg |
| Arm description: | |
| Participants started poziotinib at 24 mg QD in a 21-day cycle in the current study after having received same dose in the parent study NCT02659514. | |
| Arm type | Experimental |
| Investigational medicinal product name | Poziotinib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Modified-release tablet |
| Routes of administration | Oral use |
| Dosage and administration details: | |
| Poziotinib 24 mg administered orally, once daily | |

| Number of subjects in period 1 | Poziotinib 6 mg | Poziotinib 8 mg | Poziotinib 12 mg |
|---|-----------------|-----------------|------------------|
| Started | 1 | 1 | 1 |
| Completed | 0 | 0 | 0 |
| Not completed | 1 | 1 | 1 |
| Initiation of another anti-malignancy therapy | - | - | 1 |
| Consent withdrawn by subject | - | - | - |
| Disease progression | - | 1 | - |
| Adverse event, non-fatal | - | - | - |
| Study terminated by sponsor | 1 | - | - |

| Number of subjects in period 1 | Poziotinib 14 mg | Poziotinib 16 mg | Poziotinib 24 mg |
|---|------------------|------------------|------------------|
| Started | 1 | 2 | 1 |
| Completed | 0 | 0 | 0 |
| Not completed | 1 | 2 | 1 |
| Initiation of another anti-malignancy therapy | - | - | - |
| Consent withdrawn by subject | 1 | - | - |
| Disease progression | - | 1 | 1 |
| Adverse event, non-fatal | - | 1 | - |
| Study terminated by sponsor | - | - | - |

Baseline characteristics

Reporting groups

| | |
|--|------------------|
| Reporting group title | Poziotinib 6 mg |
| Reporting group description: Participants started poziotinib 6 mg twice a day (BID) in a 21-day cycle in the current study after having received 16 mg once daily (QD) in the parent study NCT03318939. | |
| Reporting group title | Poziotinib 8 mg |
| Reporting group description: Participants started poziotinib 8 mg QD in a 21-day cycle in the current study after having received 16 mg QD in the parent study NCT03318939. | |
| Reporting group title | Poziotinib 12 mg |
| Reporting group description: Participants started poziotinib 12 mg QD in a 21-day cycle in the current study after having received same dose in the parent study NCT03318939. | |
| Reporting group title | Poziotinib 14 mg |
| Reporting group description: Participants started poziotinib 14 mg QD in a 21-day cycle in the current study after having received 16 mg QD in the parent study NCT03318939. | |
| Reporting group title | Poziotinib 16 mg |
| Reporting group description: Participants started poziotinib at 16 mg QD in a 21-day cycle in the current study after having received 12 mg QD in the parent study NCT03804515. | |
| Reporting group title | Poziotinib 24 mg |
| Reporting group description: Participants started poziotinib at 24 mg QD in a 21-day cycle in the current study after having received same dose in the parent study NCT02659514. | |

| Reporting group values | Poziotinib 6 mg | Poziotinib 8 mg | Poziotinib 12 mg |
|---|-----------------|-----------------|------------------|
| Number of subjects | 1 | 1 | 1 |
| Age categorical Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 0 | 0 | 0 |
| From 65-84 years | 1 | 1 | 1 |
| 85 years and over | 0 | 0 | 0 |
| Gender categorical Units: Subjects | | | |
| Female | 0 | 1 | 1 |
| Male | 1 | 0 | 0 |

| Reporting group values | Poziotinib 14 mg | Poziotinib 16 mg | Poziotinib 24 mg |
|------------------------|------------------|------------------|------------------|
| Number of subjects | 1 | 2 | 1 |

| | | | |
|---|---|---|---|
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 1 | 2 | 1 |
| From 65-84 years | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 0 | 1 | 1 |
| Male | 1 | 1 | 0 |

| | | | |
|---|-------|--|--|
| Reporting group values | Total | | |
| Number of subjects | 7 | | |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | | |
| Newborns (0-27 days) | 0 | | |
| Infants and toddlers (28 days-23 months) | 0 | | |
| Children (2-11 years) | 0 | | |
| Adolescents (12-17 years) | 0 | | |
| Adults (18-64 years) | 4 | | |
| From 65-84 years | 3 | | |
| 85 years and over | 0 | | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 4 | | |
| Male | 3 | | |

End points

End points reporting groups

| | |
|--|------------------|
| Reporting group title | Poziotinib 6 mg |
| Reporting group description: Participants started poziotinib 6 mg twice a day (BID) in a 21-day cycle in the current study after having received 16 mg once daily (QD) in the parent study NCT03318939. | |
| Reporting group title | Poziotinib 8 mg |
| Reporting group description: Participants started poziotinib 8 mg QD in a 21-day cycle in the current study after having received 16 mg QD in the parent study NCT03318939. | |
| Reporting group title | Poziotinib 12 mg |
| Reporting group description: Participants started poziotinib 12 mg QD in a 21-day cycle in the current study after having received same dose in the parent study NCT03318939. | |
| Reporting group title | Poziotinib 14 mg |
| Reporting group description: Participants started poziotinib 14 mg QD in a 21-day cycle in the current study after having received 16 mg QD in the parent study NCT03318939. | |
| Reporting group title | Poziotinib 16 mg |
| Reporting group description: Participants started poziotinib at 16 mg QD in a 21-day cycle in the current study after having received 12 mg QD in the parent study NCT03804515. | |
| Reporting group title | Poziotinib 24 mg |
| Reporting group description: Participants started poziotinib at 24 mg QD in a 21-day cycle in the current study after having received same dose in the parent study NCT02659514. | |

Primary: Number of Participants With Adverse Events (AEs)

| | |
|---|---|
| End point title | Number of Participants With Adverse Events (AEs) ^[1] |
| End point description: An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Analysis population included all participants who had previous exposure to poziotinib. The Safety Analysis Population included all the enrolled participants who received at least one dose of poziotinib. | |
| End point type | Primary |
| End point timeframe: Up to 40 days after the last dose of the study drug (Up to 197 weeks) | |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analysis was planned for this endpoint.

| End point values | Poziotinib 6 mg | Poziotinib 8 mg | Poziotinib 12 mg | Poziotinib 14 mg |
|--|-----------------|-----------------|------------------|------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 1 | 1 | 1 | 1 |
| Units: subjects | | | | |
| Number of Participants With Adverse Events (AEs) | 1 | 1 | 1 | 1 |

| End point values | Poziotinib 16 mg | Poziotinib 24 mg | | |
|--|------------------|------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 2 | 1 | | |
| Units: subjects | | | | |
| Number of Participants With Adverse Events (AEs) | 2 | 1 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Response Rate (ORR)

| | |
|---|-----------------------------|
| End point title | Overall Response Rate (ORR) |
| End point description: | |
| ORR was defined as the percentage of participants with confirmed complete response (CR) and partial response (PR) as assessed by the investigator using local radiology evaluation according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1). CR is defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes must have a reduction in the short axis to <10 millimeters (mm). PR is defined as at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. As the study was terminated early due to a business decision, with lack of enrollment, the data for this outcome measure was not collected or analyzed as planned. | |
| End point type | Secondary |
| End point timeframe: | |
| Up to 191 weeks | |

| End point values | Poziotinib 6 mg | Poziotinib 8 mg | Poziotinib 12 mg | Poziotinib 14 mg |
|---|------------------|------------------|------------------|------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 0 ^[2] | 0 ^[3] | 0 ^[4] | 0 ^[5] |
| Units: percentage of subjects | | | | |
| Overall Number of Participants Analyzed | | | | |

Notes:

[2] - The study was terminated early due to business decision, the data was not analyzed as planned.

[3] - The study was terminated early due to business decision, the data was not analyzed as planned.

[4] - The study was terminated early due to business decision, the data was not analyzed as planned.

[5] - The study was terminated early due to business decision, the data was not analyzed as planned.

| End point values | Poziotinib 16 mg | Poziotinib 24 mg | | |
|---|------------------|------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 0 ^[6] | 0 ^[7] | | |
| Units: percentage of subjects | | | | |
| Overall Number of Participants Analyzed | | | | |

Notes:

[6] - The study was terminated early due to business decision, the data was not analyzed as planned.

[7] - The study was terminated early due to business decision, the data was not analyzed as planned.

Statistical analyses

No statistical analyses for this end point

Secondary: Disease Control Rate (DCR)

| | |
|-----------------|----------------------------|
| End point title | Disease Control Rate (DCR) |
|-----------------|----------------------------|

End point description:

DCR is defined as percentage of participants with best response of CR, PR, and stable disease (SD) from the first dose of poziotinib to the end of study. CR is defined as disappearance of all target and non-target lesions. Any pathological lymph nodes must have reduction in short axis to <10 mm. PR is defined as at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study. As the study was terminated early due to a business decision, with lack of enrollment, the data for this outcome measure was not collected or analyzed as planned.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to 191 weeks

| End point values | Poziotinib 6 mg | Poziotinib 8 mg | Poziotinib 12 mg | Poziotinib 14 mg |
|---|------------------|------------------|-------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 0 ^[8] | 0 ^[9] | 0 ^[10] | 0 ^[11] |
| Units: percentage of subjects | | | | |
| Overall Number of Participants Analyzed | | | | |

Notes:

[8] - The study was terminated early due to business decision, the data was not analyzed as planned.

[9] - The study was terminated early due to business decision, the data was not analyzed as planned.

[10] - The study was terminated early due to business decision, the data was not analyzed as planned.

[11] - The study was terminated early due to business decision, the data was not analyzed as planned.

| End point values | Poziotinib 16 mg | Poziotinib 24 mg | | |
|---|-------------------|-------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 0 ^[12] | 0 ^[13] | | |
| Units: percentage of subjects | | | | |
| Overall Number of Participants Analyzed | | | | |

Notes:

[12] - The study was terminated early due to business decision, the data was not analyzed as planned.

[13] - The study was terminated early due to business decision, the data was not analyzed as planned.

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of Response (DOR)

| | |
|--|----------------------------|
| End point title | Duration of Response (DOR) |
| End point description: Duration of response was defined as the time from the date that measurement criteria are first met for CR or PR until the first subsequent date that progressive disease or death is documented. CR is defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes must have a reduction in the short axis to <10 mm. PR is defined as at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. Disease progression is defined as $\geq 20\%$ increase in the sum of diameters of target lesions, unequivocal progression in non-target lesions, and/or appearance of new lesions. As the study was terminated early due to a business decision, with lack of enrollment, the data for this outcome measure was not collected or analyzed as planned. | |
| End point type | Secondary |
| End point timeframe: Up to 191 Weeks | |

| End point values | Poziotinib 6 mg | Poziotinib 8 mg | Poziotinib 12 mg | Poziotinib 14 mg |
|---|-------------------|-------------------|-------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 0 ^[14] | 0 ^[15] | 0 ^[16] | 0 ^[17] |
| Units: Months | | | | |
| Overall Number of Participants Analyzed | | | | |

Notes:

[14] - The study was terminated early due to business decision, the data was not analyzed as planned.

[15] - The study was terminated early due to business decision, the data was not analyzed as planned.

[16] - The study was terminated early due to business decision, the data was not analyzed as planned.

[17] - The study was terminated early due to business decision, the data was not analyzed as planned.

| End point values | Poziotinib 16 mg | Poziotinib 24 mg | | |
|---|-------------------|-------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 0 ^[18] | 0 ^[19] | | |
| Units: Months | | | | |
| Overall Number of Participants Analyzed | | | | |

Notes:

[18] - The study was terminated early due to business decision, the data was not analyzed as planned.

[19] - The study was terminated early due to business decision, the data was not analyzed as planned.

Statistical analyses

No statistical analyses for this end point

Secondary: Progression Free Survival (PFS)

| | |
|--|---------------------------------|
| End point title | Progression Free Survival (PFS) |
| End point description: PFS was the duration of time from first administration of study treatment to date of first documented disease progression or death from any cause. Per RECIST v1.1 for target lesions, PD was defined as $\geq 20\%$ increase in the sum of diameters of target lesions, unequivocal progression in non-target lesions, and/or appearance of new lesions. As the study was terminated early due to a business decision, with lack of enrollment, the data for this outcome measure was not collected or analyzed as planned. | |
| End point type | Secondary |
| End point timeframe: Up to 191 Weeks | |

| End point values | Poziotinib 6 mg | Poziotinib 8 mg | Poziotinib 12 mg | Poziotinib 14 mg |
|---|-------------------|-------------------|-------------------|-------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 0 ^[20] | 0 ^[21] | 0 ^[22] | 0 ^[23] |
| Units: Months | | | | |
| Overall Number of Participants Analyzed | | | | |

Notes:

[20] - The study was terminated early due to business decision, the data was not analyzed as planned.

[21] - The study was terminated early due to business decision, the data was not analyzed as planned.

[22] - The study was terminated early due to business decision, the data was not analyzed as planned.

[23] - The study was terminated early due to business decision, the data was not analyzed as planned.

| End point values | Poziotinib 16 mg | Poziotinib 24 mg | | |
|---|-------------------|-------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 0 ^[24] | 0 ^[25] | | |
| Units: Months | | | | |
| Overall Number of Participants Analyzed | | | | |

Notes:

[24] - The study was terminated early due to business decision, the data was not analyzed as planned.

[25] - The study was terminated early due to business decision, the data was not analyzed as planned.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to 40 days after the last dose of the study drug (Up to 197 weeks)

Adverse event reporting additional description:

The Safety Analysis Population included all the enrolled participants who received at least one dose of poziotinib.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 21.1 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|-----------------|
| Reporting group title | Poziotinib 6 mg |
|-----------------------|-----------------|

Reporting group description:

Participants started poziotinib 6 mg twice a day (BID) in a 21-day cycle in the current study after having received 16 mg once daily (QD) in the parent study NCT03318939.

| | |
|-----------------------|-----------------|
| Reporting group title | Poziotinib 8 mg |
|-----------------------|-----------------|

Reporting group description:

Participants started poziotinib 8 mg QD in a 21-day cycle in the current study after having received 16 mg QD in the parent study NCT03318939.

| | |
|-----------------------|------------------|
| Reporting group title | Poziotinib 12 mg |
|-----------------------|------------------|

Reporting group description:

Participants started poziotinib 12 mg QD in a 21-day cycle in the current study after having received same dose in the parent study NCT03318939.

| | |
|-----------------------|------------------|
| Reporting group title | Poziotinib 14 mg |
|-----------------------|------------------|

Reporting group description:

Participants started poziotinib 14 mg QD in a 21-day cycle in the current study after having received 16 mg QD in the parent study NCT03318939.

| | |
|-----------------------|------------------|
| Reporting group title | Poziotinib 16 mg |
|-----------------------|------------------|

Reporting group description:

Participants started poziotinib at 16 mg QD in a 21-day cycle in the current study after having received 12 mg QD in the parent study NCT03804515.

| | |
|-----------------------|------------------|
| Reporting group title | Poziotinib 24 mg |
|-----------------------|------------------|

Reporting group description:

Participants started poziotinib at 24 mg QD in a 21-day cycle in the current study after having received same dose in the parent study NCT02659514.

| Serious adverse events | Poziotinib 6 mg | Poziotinib 8 mg | Poziotinib 12 mg |
|---|-----------------|-----------------|------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 1 (0.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Gastrointestinal disorders | | | |
| Ascites | | | |

| | | | |
|---|---------------|---------------|---------------|
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Nephrolithiasis | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Poziotinib 14 mg | Poziotinib 16 mg | Poziotinib 24 mg |
|---|------------------|------------------|------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Gastrointestinal disorders | | | |
| Ascites | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Nephrolithiasis | | | |

| | | | |
|---|---------------|----------------|---------------|
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Dehydration | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Poziotinib 6 mg | Poziotinib 8 mg | Poziotinib 12 mg |
|---|-----------------|-----------------|------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 1 / 1 (100.00%) | 1 / 1 (100.00%) | 1 / 1 (100.00%) |
| Vascular disorders | | | |
| Hypotension | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chills | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Fatigue | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mucosal inflammation | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Reproductive system and breast disorders | | | |

| | | | |
|---|--|--|--|
| Breast pain subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 | 1 / 1 (100.00%) 1 |
| Respiratory, thoracic and mediastinal disorders Dysphonia subjects affected / exposed occurrences (all) Epistaxis subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 0 / 1 (0.00%) 0 |
| Psychiatric disorders Anxiety subjects affected / exposed occurrences (all) Confusional state subjects affected / exposed occurrences (all) Insomnia subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 0 / 1 (0.00%) 0 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 0 / 1 (0.00%) 0 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 0 / 1 (0.00%) 0 0 / 1 (0.00%) 0 |
| Investigations Amylase Increased subjects affected / exposed occurrences (all) Aspartate aminotransferase increased subjects affected / exposed occurrences (all) Blood creatinine increased subjects affected / exposed occurrences (all) Lipase increased subjects affected / exposed occurrences (all) Lymphocyte count decreased subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 0 / 1 (0.00%) 0 1 / 1 (100.00%) 1 0 / 1 (0.00%) 0 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 0 / 1 (0.00%) 0 0 / 1 (0.00%) 0 0 / 1 (0.00%) 0 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 0 / 1 (0.00%) 0 1 / 1 (100.00%) 1 0 / 1 (0.00%) 0 0 / 1 (0.00%) 0 |

| | | | |
|--|--------------------|----------------------|----------------------|
| Neutrophil count increased subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 1 / 1 (100.00%) 1 | 0 / 1 (0.00%) 0 |
| Weight decreased subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 |
| White blood cell count increased subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 1 / 1 (100.00%) 1 | 0 / 1 (0.00%) 0 |
| Injury, poisoning and procedural complications | | | |
| Contusion subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 |
| Skin abrasion subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 | 1 / 1 (100.00%) 2 |
| Skin laceration subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 | 1 / 1 (100.00%) 1 |
| Cardiac disorders | | | |
| Sinus tachycardia subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 |
| Nervous system disorders | | | |
| Ataxia subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 |
| Dizziness subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 |
| Headache subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 |
| Lethargy subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 |

| | | | |
|---|----------------------|----------------------|-----------------------|
| Peripheral sensory neuropathy subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 | 1 / 1 (100.00%) 1 |
| Peroneal nerve palsy subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 | 1 / 1 (100.00%) 1 |
| Syncope subjects affected / exposed occurrences (all) | 1 / 1 (100.00%) 1 | 0 / 1 (0.00%) 0 | 1 / 1 (100.00%) 1 |
| Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 | 1 / 1 (100.00%) 1 |
| International normalised ratio increased subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 |
| Eye disorders Eye irritation subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 | 1 / 1 (100.00%) 1 |
| Vision blurred subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 |
| Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 |
| Diarrhoea subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 1 / 1 (100.00%) 1 | 1 / 1 (100.00%) 16 |
| Gastrooesophageal reflux disease subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 |
| Nausea subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 |

| | | | |
|--|---------------|-----------------|-----------------|
| Stomatitis | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Skin and subcutaneous tissue disorders | | | |
| Alopecia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 1 (100.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Dermatitis acneiform | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry skin | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 1 (100.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 4 | 0 |
| Skin atrophy | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hematuria | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Proteinuria | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nephrolithiasis | | | |

| | | | |
|--|--------------------|--------------------|--------------------|
| subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Flank pain | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscle spasms | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Osteoarthritis | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Infections and infestations | | | |
| Nasopharyngitis | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Paronychia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 1 (100.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 0 | 1 | 2 |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 1 / 1 (100.00%) | 0 / 1 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypoalbuminaemia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypokalaemia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyponatraemia | | | |

| | | | |
|-----------------------------|---------------|---------------|-----------------|
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Dehydration | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 1 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| Non-serious adverse events | Poziotinib 14 mg | Poziotinib 16 mg | Poziotinib 24 mg |
|---|------------------|------------------|------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 1 / 1 (100.00%) | 2 / 2 (100.00%) | 1 / 1 (100.00%) |
| Vascular disorders | | | |
| Hypotension | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Chills | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 2 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fatigue | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 2 / 2 (100.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Mucosal inflammation | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 2 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Reproductive system and breast disorders | | | |
| Breast pain | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 2 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Dysphonia | | | |

| | | | |
|--------------------------------------|---------------|----------------|---------------|
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Epistaxis | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Confusional state | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Insomnia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Investigations | | | |
| Amylase Increased | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Lipase increased | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Lymphocyte count decreased | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Neutrophil count increased | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Weight decreased | | | |

| | | | |
|--|--------------------|---------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 1 / 2 (50.00%) 2 | 0 / 1 (0.00%) 0 |
| White blood cell count increased subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 | 0 / 1 (0.00%) 0 |
| Injury, poisoning and procedural complications | | | |
| Contusion subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 1 / 2 (50.00%) 1 | 0 / 1 (0.00%) 0 |
| Skin abrasion subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 | 0 / 1 (0.00%) 0 |
| Skin laceration subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 | 0 / 1 (0.00%) 0 |
| Cardiac disorders | | | |
| Sinus tachycardia subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 1 / 2 (50.00%) 1 | 0 / 1 (0.00%) 0 |
| Nervous system disorders | | | |
| Ataxia subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 | 1 / 1 (100.00%) 1 |
| Dizziness subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 1 / 2 (50.00%) 1 | 0 / 1 (0.00%) 0 |
| Headache subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 | 1 / 1 (100.00%) 1 |
| Lethargy subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 1 / 2 (50.00%) 1 | 0 / 1 (0.00%) 0 |
| Peripheral sensory neuropathy subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 | 0 / 1 (0.00%) 0 |
| Peroneal nerve palsy | | | |

| | | | |
|---|----------------------|----------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 | 0 / 1 (0.00%) 0 |
| Syncope subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 | 0 / 1 (0.00%) 0 |
| Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 1 / 2 (50.00%) 1 | 0 / 1 (0.00%) 0 |
| International normalised ratio increased subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 1 / 2 (50.00%) 1 | 0 / 1 (0.00%) 0 |
| Eye disorders Eye irritation subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 | 0 / 1 (0.00%) 0 |
| Vision blurred subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 2 (0.00%) 0 | 1 / 1 (100.00%) 1 |
| Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 1 / 2 (50.00%) 1 | 0 / 1 (0.00%) 0 |
| Diarrhoea subjects affected / exposed occurrences (all) | 1 / 1 (100.00%) 5 | 1 / 2 (50.00%) 1 | 0 / 1 (0.00%) 0 |
| Gastrooesophageal reflux disease subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 2 / 2 (100.00%) 2 | 0 / 1 (0.00%) 0 |
| Nausea subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 1 / 2 (50.00%) 4 | 0 / 1 (0.00%) 0 |
| Stomatitis subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 1 / 2 (50.00%) 1 | 0 / 1 (0.00%) 0 |
| Vomiting | | | |

| | | | |
|--|--------------------|---------------------|--------------------|
| subjects affected / exposed occurrences (all) | 0 / 1 (0.00%) 0 | 1 / 2 (50.00%) 2 | 0 / 1 (0.00%) 0 |
| Skin and subcutaneous tissue disorders | | | |
| Alopecia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 2 / 2 (100.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Dermatitis acneiform | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 7 | 0 |
| Dry skin | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Rash | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 2 / 2 (100.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 4 | 0 |
| Skin atrophy | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Hematuria | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Proteinuria | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nephrolithiasis | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Musculoskeletal and connective tissue disorders | | | |

| | | | |
|------------------------------------|-----------------|----------------|---------------|
| Flank pain | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Muscle spasms | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Osteoarthritis | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 2 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infections and infestations | | | |
| Nasopharyngitis | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 2 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Paronychia | | | |
| subjects affected / exposed | 1 / 1 (100.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 6 | 1 | 0 |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 2 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypoalbuminaemia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Hypokalaemia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 2 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dehydration | | | |

| | | | |
|-----------------------------|---------------|----------------|---------------|
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 2 (50.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|------------------|--|
| 27 November 2019 | <ol style="list-style-type: none">1. This study has been open to all participants who have had previous exposure to poziotinib, including participants in Investigator-Initiated Studies (IIS) as long as the participant is receiving clinical benefit, as judged by the Investigator or treating physician.2. In order to conduct analyses with data from these participants, specific assessments and their timing have been added:<ul style="list-style-type: none">• Addition of a summary of assessments and procedures table.• Assessments must be at least every 2 cycles of treatment• Added detailed explanations for assessments and procedures in Section 5, Study Procedures3. The participant's last dose before entering the study was changed from "cannot be more than 20 days" to "cannot be more than 28 days".4. The study title changed to "An Open-Label Extension Study to Allow Continued Dosing and/or Follow-up of Patients who have had Previous Exposure to Poziotinib" from "An Open-Label Extension Study to Allow Continued Treatment of Patients who have Participated in a Spectrum-Sponsored Poziotinib Study".5. The primary objective changed to "To continue to monitor patients who appear to derive clinical benefit from poziotinib" from "To continue to provide clinical benefit to patients who have participated in Spectrum-sponsored studies with poziotinib".6. Removal of inclusion criteria "Patient did not meet any treatment discontinuation criteria other than completing maximum treatment time of the original Spectrum-sponsored Study".7. Removal of exclusion criteria "Patient is receiving any other treatment modalities with curative intent for his or her malignancy, including investigational products other than poziotinib. Therapies to palliate local symptoms will be allowed (e.g. radiation for focal bone metastasis).8. Addition of exclusion criteria "Patient's last dose of poziotinib was more than 28 days prior to Day 1 of the study". |
| 27 November 2019 | <ol style="list-style-type: none">9. Removed the reference to SPI-POZ-102 and stated that participants can be treated at their last dose or at 16 mg/day in Section 6.1.3: Poziotinib Administration.10. Added the standard dose modification instructions that are used in other poziotinib studies in Section 6.4: Poziotinib Dose Delays and Modifications. Dose reductions below 8 mg are not recommended in the study.11. The evaluation of participants and the collecting of data was formalized in Section 5.1: Screening. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

| Date | Interruption | Restart date |
|---------------|--|--------------|
| 03 March 2023 | Study was terminated due to business reasons, not related to safety. | - |

Notes:

Limitations and caveats

None reported